inhalED™ Clinical Evaluation Summary

Real-World Observational Outcomes in Men Currently Using Tadalafil Therapy

 

Executive Summary

A clinical evaluation summary was conducted to assess the real-world performance, tolerability, and user experience of inhalED™, a novel inhalation-based delivery system designed to support erectile response. The evaluation was performed in adult male participants who were already established users of tadalafil therapy, allowing for direct experiential comparison.

Findings from this evaluation indicate that inhalED™ was associated with rapid perceived onset, favorable tolerability, and reduced recovery time, with minimal reported adverse effects. The consistency of reported outcomes across participants supports inhalED™’s potential as a differentiated delivery platform with clinically meaningful advantages over traditional sublingual formulations.

Evaluation Design

Evaluation Type: Clinical evaluation summary based on real-world observational outcomes

Participants: Adult males, 38–72 years

Baseline Therapy: Tadalafil troches, 40 mg scored into quarters

Baseline Typical Dosing: ½ troche dissolved sublingually approximately 30 minutes prior to sexual activity

Intervention: Trial-size samples of inhalED™, featuring 25 mg Sildenafil

Primary Observational Endpoints:

• Perceived onset speed
• Tolerability and side-effect profile
• Recovery time following sexual activity
• Ease of use and delivery acceptability

No changes were made to participants’ baseline therapy outside the evaluation period, and participants were able to assess inhalED™ relative to an established and familiar standard of care.

Observational Outcomes

Perceived Onset of Action
A strong majority of participants reported rapid perceived onset, frequently describing the response as faster than their usual sublingual tadalafil regimen. This observation is consistent with the known absorption advantages of inhalation-based delivery systems.

Tolerability Profile
Approximately 70% of participants reported no headache, heartburn, or musculoskeletal discomfort, side effects commonly reported with oral and sublingual PDE-5 therapies. Overall tolerability was rated favorably across the cohort.

Recovery Time
Most participants reported shortened recovery time following sexual activity compared with prior experience on sublingual tadalafil. While subjective, this outcome was consistently noted and viewed as a meaningful improvement.

User Experience and Acceptance
Participants uniformly described the inhalation format as novel, engaging, and innovative, with high initial acceptance. Positive first-use experience is considered an important indicator of adherence and satisfaction.

Safety and Use Considerations
No serious adverse events were reported during the evaluation. Minor usability considerations were identified, including audible inhalation during administration (non-discreet) and mechanical issues with devices used for higher-volume sampling. These findings relate to device design rather than product performance or tolerability.

Clinical Interpretation
The outcomes of this clinical evaluation summary suggest that inhalED™ provides measurable experiential benefits in a population already familiar with tadalafil therapy. The combination of faster perceived onset, improved tolerability, and reduced recovery time addresses several of the most frequently cited limitations of existing delivery formats.

Importantly, these benefits were observed without an increase in adverse effects, supporting the premise that delivery innovation alone may significantly enhance therapeutic experience.

Conclusion
Based on real-world observational outcomes, inhalED™ demonstrated a favorable performance and tolerability profile in adult men currently using tadalafil therapy. The consistency of reported benefits across participants supports continued development and refinement of inhalED™ as a clinically relevant, next-generation delivery platform.

Further evaluation in larger cohorts and controlled settings is warranted to expand upon these findings and explore long-term outcomes.

Use Statement

This document represents a clinical evaluation summary derived from observational outcomes and is not intended to represent a randomized, controlled clinical trial.